Research

The background Fingolimod was approved in 2010 and became the first oral drug for the treatment of relapsing-remitting MS (RRMS).  It has proven to be beneficial for many people with MS and works by...

The background It is known that problems with the blood-brain barrier (BBB) and the immune system contribute to the damage seen in multiple sclerosis (MS). These problems are often worsened by oxidative...

During July 2016, we have had the privilege of collaborating with Professor George Jelinek and the Neuroepidemiology Unit based at The University of Melbourne. In the first feature filmed with the group,...

The background Whilst it is generally accepted that multiple sclerosis (MS) has a combination of genetic and environmental factors that contribute to its development, the exact nature of these is still...

Research summary: Nuclear Receptor NR1H3 in Familial Multiple Sclerosis The background Whilst the cause of multiple sclerosis remains elusive, studies have shown that there are specific variations of...

Between May 20 and 22, 2016, MStranslate was invited to participate in and present at two research days organised for the local multiple sclerosis (MS) communities in both Auckland and Christchurch, New...

At the start of May, we posted an update on clinical trials that were evaluating high dose biotin as a treatment for multiple sclerosis. Undertaken by biotechnology company, medDay, the results of these trials...

Research summary:  Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor The...

INTERVIEW WITH DR LEIGH CHARVET – NYU LANGONE MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTER BD: Brett Drummond, MStranslate LC: Dr. Leigh Charvet, NYU Langone Multiple Sclerosis Comprehensive Care...

INTERVIEW WITH DR CHRISTIAN GRUBER – MEDICAL UNIVERSITY OF VIENNA AND UNIVERSITY OF QUEENSLAND BD: Brett Drummond, MStranslate CG: Dr. Christian Gruber, Medical University of Vienna & University...